Pharmacokinetic profiling of the bioactive components of Sijunzi Decoction in a ...

연구 요약

Pharmacokinetic profiling of the bioactive components of Sijunzi Decoction in a rat model of breast cancer: Insights into herb-drug interactions with cyclophosphamide.

Journal of pharmaceutical and biomedical analysis 학술지에 발표된 이 연구는 Zhang Z, Zhang Y, Gao R 외 연구팀이 수행하였습니다.

이 연구는 'Pharmacokinetic profiling of the bioactive components of Sijunzi Decoction in a rat model of breast cancer: Insights into herb-drug interactions with cyclophosphamide.'에 대한 과학적 분석을 제공합니다.

핵심 내용

This study investigated the pharmacokinetics of Sijunzi Decoction (SJZD) components and their interactions with cyclophosphamide (CTX) in breast cancer (BC) rats. The BC model was induced using 7,12-dimethylbenz[a]anthracene (DMBA). Using UPLC-Orbitrap-MS/MS, we identified 23 SJZD-derived compounds in rat plasma. Subsequently, a validated UPLC-TQ-MS/MS method was developed to quantify seven bioactive analytes. Compared with normal rats, BC model rats exhibited significantly altered pharmacokinetics: ginsenosides Rb1 and Rc showed enhanced systemic exposure and prolonged elimination, whereas the clearance of glycyrrhetinic acid was accelerated. Co-administration with CTX further increased the absorption of ginsenosides but markedly reduced the exposure and accelerated the clearance of licorice-derived compounds (liquiritin, isoliquiritigenin, formononetin, and glycyrrhetinic acid). These findings indicate that breast cancer pathology significantly alters the in vivo disposition of SJZD components, and that CTX induces complex herb-drug interactions. This study provides a critical pharmacokinetic basis for the rational clinical application of SJZD as an adjuvant therapy in breast cancer patients, particularly when combined with chemotherapy.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41762480)